Unprecedented Demand
The surge in demand for GLP-1 weight loss drugs, driven by their effectiveness and broad eligibility, is reshaping the healthcare landscape. Zach highlights how his company, initially focused on erectile dysfunction, pivoted to address obesity at the perfect moment, capitalizing on a wave of consumer interest. This convergence of timing and market need illustrates the power of being in the right place at the right time.In this clip
From this podcast
Masters of Scale
Rapid Response: Riding the Ozempic wave, w/RO's CEO Zach Reitano
Related Questions